Preclinical News and Research

RSS

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.

30 Sep 2014

VCU receives $6 million grant to develop safe, effective treatments for cocaine addiction

Virginia Commonwealth University has received a five-year, $6 million grant for clinical research and education directed toward the identification, evaluation and development of safe and effective treatments for cocaine addiction.

30 Sep 2014

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.

29 Sep 2014

International organizations join forces to develop inhaled form of oxytocin for postpartum hemorrhage

An international group of public and private organizations is collaborating to accelerate development of an innovative heat-stable and low-cost inhaled form of oxytocin to manage postpartum hemorrhage in resource-poor settings.

26 Sep 2014

New CRUK-MEDI Alliance Laboratory to focus on development of novel biologic cancer treatments

CANCER RESEARCH UK, with its commercial arm Cancer Research Technology, today announce that they have entered into an innovative collaboration with AstraZeneca and MedImmune, its global biologics research and development arm, to establish a joint laboratory in Cambridge, UK.

25 Sep 2014

Pitt researchers awarded new $5.8 million NIH grant to develop microfluidic 3D liver model system

With a new $5.8 million, three-year award from the National Institutes of Health, researchers at the University of Pittsburgh School of Medicine will further develop a state-of-the-art, microfluidic 3D model system that mimics structure and function of the liver to better predict organ physiology, assess drug toxicity and build disease models.

25 Sep 2014

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research and the Catalan Institute of Oncology was established with the aim of bringing the company the latest scientific developments to the service combating cancer with two main branches: the development of new drugs and advance the implementation of personalized cancer treatments.

24 Sep 2014

Inovio, GeneOne to advance DNA-based Ebola vaccine into phase I clinical trial

Inovio Pharmaceuticals, Inc. announced it will advance its DNA vaccine for Ebola into a phase I clinical trial in a collaboration with GeneOne Life Science Inc., an international DNA vaccine manufacturer in which Inovio holds a minority interest.

24 Sep 2014

NIH awards $10.1 million in supplemental funding to study effects of sex in preclinical, clinical studies

The National Institutes of Health has awarded $10.1 million in supplemental funding to bolster the research of 82 grantees to explore the effects of sex in preclinical and clinical studies.

24 Sep 2014

Blocking AEG-1 gene expression halts development of liver cancer by regulating inflammation

Inflammation has been shown to be a driving force behind many chronic diseases, especially liver cancer, which often develops due to chronic inflammation caused by conditions such as viral hepatitis or alcoholism and has relatively few effective treatment options.

23 Sep 2014

Oxabact now recognized as potential treatment for Short Bowel Syndrome

SBS is a highly disabling malabsorptive condition. SBS is associated with significant morbidity and mortality, reduced quality of life and high healthcare costs.

23 Sep 2014

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Avalon Ventures today announced the launch of two new companies formed through its collaboration with GlaxoSmithKline to fund and launch up to 10 early-stage life science companies.

23 Sep 2014

Propanc, Southridge Partners enter into equity purchase agreement

Propanc Health Group Corporation, an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA") with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms.

23 Sep 2014

Photoacoustics could become alternative to mammography or sonogram for breast cancer detection

One of the lines of research of OILTEBIA, a European science project coordinated by Universidad Carlos III de Madrid, is a method to detect breast cancer based on photoacoustics and which could become an alternative to mammography or sonogram.

22 Sep 2014

Researchers develop protein therapy that may stop cancer growth

A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.

22 Sep 2014

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

19 Sep 2014

New approach to imaging metastatic tumors

Bioluminescence, nanoparticles, gene manipulation - these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors.

18 Sep 2014

TSRI scientists devise new vancomycin-based antibiotic to rout resistant bacteria

Scientists at The Scripps Research Institute have devised a new antibiotic based on vancomycin that is powerfully effective against vancomycin-resistant strains of MRSA and other disease-causing bacteria.

18 Sep 2014

Preclinical News and Research

Mymetics' innovative HIV vaccine candidate to enter new preclinical trial

VCU receives $6 million grant to develop safe, effective treatments for cocaine addiction

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Combination therapy achieves greater progression-free survival, response rates in melanoma

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

International organizations join forces to develop inhaled form of oxytocin for postpartum hemorrhage

New CRUK-MEDI Alliance Laboratory to focus on development of novel biologic cancer treatments

Pitt researchers awarded new $5.8 million NIH grant to develop microfluidic 3D liver model system

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

Inovio, GeneOne to advance DNA-based Ebola vaccine into phase I clinical trial

NIH awards $10.1 million in supplemental funding to study effects of sex in preclinical, clinical studies

Blocking AEG-1 gene expression halts development of liver cancer by regulating inflammation

Oxabact now recognized as potential treatment for Short Bowel Syndrome

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Propanc, Southridge Partners enter into equity purchase agreement

Photoacoustics could become alternative to mammography or sonogram for breast cancer detection

Researchers develop protein therapy that may stop cancer growth

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

New approach to imaging metastatic tumors

TSRI scientists devise new vancomycin-based antibiotic to rout resistant bacteria

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics